📰 Mostread Technology News
Page 25 - Mostread Technology News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Mostread Technology. Real-time updates on events, politics, business and more.
October 19, 2023
Electric vehicles manufacturer Tesla posted third-quarter quarter earnings that came in below expectations on Thursday, with chief executive Elon Musk voicing concerns regarding the state of the global economy.
October 17, 2023
America's Department of Defense granted Chemring the majority of the approvals needed in order to proceed with the delivery of certain countermeasures.
October 17, 2023
Aerospace outfit Melrose upgraded its full-year guidance thanks to the continued "strong" aftermarket demand in its Engines business.
October 13, 2023
In-content advertising specialist Mirriad Advertising announced the appointment of Nicholos (Nic) Hellyer as its chief financial officer designate on Friday after recent strategic evaluations and a managerial reshuffle.
October 13, 2023
Life sciences company Ondine Biomedical announced the expansion of the availability of its Steriwave nasal photo disinfection technology on Friday across various hospitals in Canada.
October 12, 2023
Payments specialist Wise upgraded its guidance on Thursday in the wake of a solid second-quarter performance.
October 12, 2023
Maritime artificial intelligence (AI) company Windward reported a series of contract triumphs and renewals throughout its second half on Thursday, affirming a trading performance aligning with market anticipations for the year.
October 11, 2023
Vodafone’s planned merger with Three UK came under the Competition and Markets Authority (CMA) spotlight on Wednesday, as the regulator invited feedback from third parties over the impact it could have on the competitive landscape.
October 11, 2023
CentralNic Group announced that it has officially rebranded to Team Internet Group on Wednesday, following a decision subject to shareholder approval, first reported on 4 September.
October 11, 2023
Faron Pharmaceuticals announced encouraging updated data from its ongoing phase one and two ‘BEXMAB’ study into relapsed or refractory (r/r) acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS) treatments on Wednesday.